Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Oxford Lane Capital Corp (OXLC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Oxford Lane Capital Corp — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Oxford Lane Capital Corp trades at $9.11 (market cap $872.99M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 5.1× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays a 26.85% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | OXLC | |
|---|---|---|
Market Cap | $4.49B | $872.99M |
Sector | Health | Financials |
52-Week High | $28.06 | $20.80 |
52-Week Low | $20.06 | $8.15 |
Enterprise Value | $3.69B | — |
Dividend Yield | — | 26.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
OXLC trades at $8.95, up 1.59% today, with a bullish technical signal but mixed indicators. The stock shows a P/B of 0.85, suggesting potential undervaluation, but profitability metrics are weak with a -39.16% ROE. Recent earnings have consistently missed expectations, including a significant Q1 2026 EPS miss. The company maintains a regular dividend payout of $0.20 per share, supporting income-focused investors despite fundamental challenges.
Outlook remains cautious due to persistent earnings underperformance and negative ROE/ROA. High dividend yield attracts income seekers, but sustainability concerns and NAV declines pose risks. Analyst consensus is divided, with 50% buy ratings balanced by bearish sentiment from financial media. Key risks include further NAV erosion and reliance on financing cash flows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →
